venture capital

Anthropic's $400B valuation remains private, but three funds—AGIX, ARKVX, and DXYZ—offer retail exposure with varying expense ratios and strategies.

Major unicorns bypass public markets via secondary sales. Secondary market volumes hit $226B in 2025, reshaping traditional IPO pipeline.

Databricks valuation jumps 302% since Pelosi's 2024 investment, spurring 150,000 Robinhood users to seek pre-IPO exposure through new venture fund.

BBVA partners with Nasdaq Private Market to provide Latin American private companies secondary liquidity solutions including tender offers and private secondaries.

Anthropic targets 2026 IPO at $1 trillion valuation. Investors can gain exposure through stakes held by Alphabet (14%), Amazon ($4B), Salesforce (1%), and Zoom ($51M).

Thrive Capital acquires sub-10% San Francisco Giants stake via Thrive Eternal as VC pivots toward sports. Bob Iger joins as advisor amid projections of global sports market growth from $463B to $863B by 2033.

Kailera Therapeutics surged 63% on Nasdaq debut as weight-loss drug spinoff from Hengrui Pharma, raising $625M and validating the 'NewCo' model for Chinese pharmaceutical companies.

OpenAI eyes Q4 2026 IPO at $852B valuation; investors can gain pre-IPO exposure via Ark Venture Fund (11% stake) or Microsoft (27% ownership, 20% revenue share).

Peter Thiel's $55M PayPal exit contrasts sharply with his $10B Palantir stake, as PayPal faces 4-6% growth while Palantir projects 49-54% CAGRs through 2028.

Alphabet disclosed 6.11% SpaceX stake valued at $122 billion in routine Alaska filing, originating from 2015 joint investment with Fidelity.

Peter Thiel maintains ~4% stake in $PLTR worth over $13B post-IPO, signaling confidence in defense and AI market expansion.

Lockheed Martin shares fell 1.46% despite landing a $1.9B Pentagon contract and expanding its venture capital fund to $1B, as investors rotated into higher-performing sectors.

Israel Tech Week moves to Miami April 27-30, 2026, emerging as rare major tech conference continuing amid Israeli conflict while peers postpone.

Tiger Global invests in PopUp Bagels at $300M valuation, reflecting five-fold growth in five months and signaling renewed venture appetite for authentic restaurant concepts.

Incyclix Bio raises $5M from Hatteras Venture Partners for Phase 1/2 trial of INX-315, targeting therapy-resistant breast and ovarian cancers.

Eclipse closes $1.3B fundraise for hard-tech ventures in AI, robotics, manufacturing, and defense, positioning itself as operators-with-capital rather than traditional VCs.

Telehealth performance medicine company Maximus ranks #7 on Financial Times' fastest-growing firms, driven by explosive revenue growth across testosterone, GLP-1, and peptide therapies.

Glasswing Ventures appoints 14 AI and enterprise leaders from major tech firms to advisory councils, supporting portfolio companies' AI adoption and go-to-market strategies.

SpaceX's anticipated June IPO could value the company at $1.75T. Investors can gain exposure through $SATS, $GOOGL, and specialized funds before public listing.

SpaceX reportedly considers 2024 IPO at $1.75T valuation post-xAI merger. Retail investors can gain exposure through $GOOGL, ETFs, or secondary platforms.